

## Antibodies & Sera and other matrices (LAB4042 SU)

### SUMMARY

**Start date:** 1st July, 2021

**End date:** 31st December, 2023

**OJEU Number:** LAB4042 SU

**Lead Consortium:** SUPC

**Main contact:** Taron Smith  
[t.a.smith@reading.ac.uk](mailto:t.a.smith@reading.ac.uk)

**Website:**  
<https://www.hecontracts.co.uk/agreements/945>

### SCOPE

There are two lots in this agreement:

Lot 1 - Antibodies

Lot 2 - Sera and other matrices

### AGREEMENT BENEFITS

- Compliant route
- Fast route to market
- Competitive rates
- A wide choice of suppliers to match your organisational requirements and culture
- A set of standard added-value services across all suppliers, complemented by supplier specific added-value services detailed further in the tender response

### USING THE FRAMEWORK

### SUPPLIERS

Lot	Suppliers
Lot 1 - Antibodies	2BScientific Ltd, Agilent Technologies LDA UK Limited, Antibodies.com, BioServ UK Ltd, BioTechne Ltd, Biolegend, Cambridge Bioscience, Cell Signalling Technology Europe B.V, CliniSciences Limited, Enzo Life Sciences, Fisher Scientific UK Ltd, Insight Biotechnology, Merck Life Science UK Limited, Miltenyi Biotec Ltd, Oxford Biosystems Ltd, Proteintech Europe Ltd, Stratech Scientific Ltd, Takara (Clontech) Bio Europe SAS,
Lot 2 - Sera and other matrices	2BScientific Ltd, Agilent Technologies LDA UK Limited, Antibodies.com, BioServ UK Ltd, Fisher Scientific UK Ltd, Merck Life Science UK Limited, Stratech Scientific Ltd, Takara (Clontech) Bio Europe SAS,

### SUSTAINABILITY

### NEXT STEPS